BMC Biotechnology Volume 7
|
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
 Research articleChaperone-based procedure to increase yields of soluble recombinant proteins produced in E. coliArio de Marco1,2 , Elke Deuerling3 , Axel Mogk3 , Toshifumi Tomoyasu4 and Bernd Bukau3  1EMBL Heidelberg, Meyerhofstrasse 1, D-69117 Heidelberg, Germany 2IFOM-IEO Campus for Oncogenomics, via Adamello 16, I-20139, Milano, Italy 3ZMBH, Universität Heidelberg, Im Neuenheimer Feld 282, D-69120 Heidelberg, Germany 4Department of Microbiology and Molecular Genetics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-33 Yayoicho, Inageku, Chiba 263-8522, Japan author email corresponding author email
BMC Biotechnology 2007,
7:32doi:10.1186/1472-6750-7-32 Abstract
Background
The overproduction of recombinant proteins in host cells often leads to their misfolding and aggregation. Previous attempts to increase the solubility of recombinant proteins by co-overproduction of individual chaperones were only partially successful. We now assessed the effects of combined overproduction of the functionally cooperating chaperone network of the E. coli cytosol on the solubility of recombinant proteins.
Results
A two-step procedure was found to show the strongest enhancement of solubility. In a first step, the four chaperone systems GroEL/GroES, DnaK/DnaJ/GrpE, ClpB and the small HSPs IbpA/IbpB, were coordinately co-overproduced with recombinant proteins to optimize de novo folding. In a second step, protein biosynthesis was inhibited to permit chaperone mediated refolding of misfolded and aggregated proteins in vivo. This novel strategy increased the solubility of 70% of 64 different heterologous proteins tested up to 42-fold.
Conclusion
The engineered E. coli strains and the two-step procedure presented here led to a remarkable increase in the solubility of a various recombinant proteins and should be applicable to a wide range of target proteins produced in biotechnology. |